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We tested serum specimens from three groups of patients with pneumonia
by indirect immunofluorescence against Legionella-like amoebal pathogens
(LLAPs) 1–7, 9, 10, 12, 13; Parachlamydia acanthamoeba strains BN 9 and
Hall’s coccus; and Afipia felis. We found that LLAPs play a role (albeit an
infrequent one) in community-acquired pneumonia, usually as a co-patho-
gen but sometimes as the sole identified pathogen. 
A number of bacteria that grow only within amoebae
and are closely related phylogenetically to  Legionella  spe-
cies, Legionella-like amoebal pathogens (LLAPs), have been
identified and characterized (1). The role of these bacteria as
human pathogens is still largely unknown. Other microor-
ganisms, e.g.,  Parachlamydia acanthamoeba strains BN 9
(2) and Hall’s coccus (3), also grow within amoebae. Afipia
felis (once thought to be the etiologic agent of cat-scratch dis-
ease), a gram-negative rod, is difficult to grow on artificial
medium but grows well in human monocytes and HeLa cells
(4); this organism was recently reported to be an environ-
mental bacterium probably associated with free-living amoe-
bae and living in water (5). We tested serum specimens from
three groups of patients with pneumonia to determine if any
of these microorganisms cause disease. 
The Study
We used 511 specimens from a 1985 study of a random
sample of the Nova Scotia population (6); 121 acute- and con-
valescent-phase serum specimens from a study (Nova Scotia,
1991-1994) of 149 ambulatory patients with community-
acquired pneumonia (7); and specimens from a prospective
study of community-acquired pneumonia requiring hospital-
ization conducted at 15 teaching hospitals in eight Canadian
provinces (1996-1997). 
All serum specimens from both groups of patients with
pneumonia were tested for antibodies to Mycoplasma pneu-
moniae; influenza viruses A and B; parainfluenza viruses
1,2,3; adenovirus; and Respiratory syncytial virus (RSV) by a
standard complement fixation technique in microtiter plates.
Serum specimens from 60% of the patients (randomly
selected from the group of patients with community-acquired
pneumonia requiring hospitalization) were tested by the
microimmunofluorescence test (8-10) for immunoglobulin (Ig)
G and IgM antibodies to  Chlamydia pneumoniae (AR 39
strain);  C. psittaci (avian strain 6BC, feline pneumonitis
strain FP, turkey strain TT 3, and pigeon strain CP 3); C.
pecorum (ovine polyarthritis strain); and C. trachomatis
(pooled antigens of serovars BED, CJHI, and FGK). Serum
specimens from hospitalized patients with pneumonia were
tested for antibodies to  Streptococcus pneumoniae pneumo-
lysin, pneumolysin immune complexes, C polysaccharide,
surface protein A, Haemophilus influenzae, and Branhamella
catarrhalis by Dr. M. Leinonen, National Public Health Insti-
tute, Oulu, Finland, as reported previously (11-13).
Acute- and convalescent-phase serum specimens from
150 patients also had been previously tested by enzyme-
linked immunosorbent assay (ELISA) for antibodies to
L.pneumophila serogroups 1–6 by Yu (14). A urine sample
collected from each patient within 24 hours of hospitaliza-
tion was tested for L. pneumophila serogroup 1 antigen by
ELISA (15) (Binax, Inc., Portland, ME). Antibodies to Cox-
iella burnetii  phase 1 and 11 antigens and to  Chlamydia
pneumoniae were determined by a microimmunofluores-
cence test, as described (16,17).
Antibody titers to LLAPs also were determined by the
indirect fluorescent antibody technique. These included
Acanthamoeba polyphaga strain Linc AP 1 and LLAP
strains 1, 2, 4, 6, 7, 9, 10, 12; L. lytica (strains LLAP 3 and
L2, formerly Sarcobium lyticum); and Parachlamydia acan-
thamoeba (strain BN 9 and Hall’s coccus).  A. felis ATCC
53690 was from the American Type Culture Collection.
LLAPs were cultured in A. polyphaga in 150 peptone-yeast
extract-glucose broth (18) at 30°C. When maximally infected,
amoebae were lysed through three cycles of freeze-thawing
in liquid nitrogen. This suspension was then resuspended in
30 mL of phosphate-buffered saline and centrifuged at
10,000 rpm for 10 minutes. Supernatant fluid was removed,
and pellets containing respective LLAPs were resuspended
in the smallest possible volume of sterile distilled water and
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were adjusted to a concentration of 2 mg/mL, as determined
spectrophotometrically. Antigen prepared in this manner
was frozen at –20°C until required.
Specimens with an IgM titer of  >1:100, seroconversion
from 0 to 100, a fourfold rise in antibody titer between acute-
and convalescent-phase serum, and a single or stable titer of
>400 were considered indicative of recent infection. An anti-
body titer of >50 was considered seropositive, i.e., evidence of
prior but not recent infection.
The seropositivity rate to various antigens is shown in
Table 1. The background rate of such infection is low. Only
one healthy Nova Scotian had serologic evidence of recent
infection with an LLAP, LLAP 4. None of the patients with
ambulatory pneumonia had such an infection. LLAP 4 was
the most common LLAP-causing pneumonia: four such infec-
tions among patients with community-acquired pneumonia
required hospitalization. Two of the 58 patients from the
Nova Scotia site had infection with LLAP 4, versus one of
511 healthy Nova Scotians (p<0.029, Fisher exact test). BN 9
caused two infections, and LLAP 1 and 12 caused one each
among patients with community-acquired pneumonia
requiring hospitalization. 
Case Histories
LLAP 1 and 12 Infections
A 40-year-old floral designer was hospitalized in Edmon-
ton, Alberta, with a 21-day history of diarrhea, myalgias,
headache, chills, and shortness of breath. She had traveled
to Los Angeles and Palm Springs in the previous 10 days. On
admission, her oral temperature was 36.9°C, and fine
bilateral interstitial infiltrates were present on a chest
radiograph. She was treated with erythromycin and doxycy-
cline, was discharged on day 7, and was readmitted 2 weeks
later, at which time a transbronchial biopsy specimen
yielded  Mycobacterium avium intracellulare on culture. No
evidence of HIV infection was found. The acute- and conva-
lescent-phase antibody titers to LLAP 1 were 1:400 in the
IgG fraction and 1:25 and 0 in the IgM fraction.
A 34-year-old clerical worker in a hospital radiology
department was hospitalized on April 11, 1996, with pleu-
ritic chest pain and shortness of breath of 10 days’ duration.
Her oral temperature was 38.7°C. The leukocyte count was
9.2 x 109  /L. A chest radiograph showed multilobar patchy
opacities on the left and a 3-cm nodular opacity on the right.
The patient was treated with erythromycin and cefuroxime
intravenously for 36 hours, followed by oral clarithromycin.
The nodule did not resolve over the next 6 weeks, and an
open lung biopsy was performed. All cultures were negative.
Histologic examination revealed acute and chronic inflam-
mation. The acute-phase serum sample had an IgM antibody
titer of 1:200 to LLAP 12, and the convalescent-phase titer
was 1:100; the corresponding values for IgG were 0 and 1:50.
BN 9 Infection
A 21-year-old university student was hospitalized with
fever, abdominal pain, nausea, vomiting, diarrhea, pleuritic
chest pain, and nonproductive cough. He also complained of
a sore throat and shortness of breath. On examination, he
looked acutely ill and had a diffuse erythematous rash. His
oral temperature was 38.3°C. A chest radiograph showed dif-
fuse opacities involving both lower lobes. He was treated
with erythromycin. The next day desquamation of the lips
and the skin of the digits was noted, and a diagnosis of adult
Kawasaki disease was entertained. Treatment with aspirin
and gamma globulin was instituted, and the patient made
an uneventful recovery. There was no evidence of cardiac
involvement as indicated by normal serial electrocardio-
grams and a normal echocardiogram. The BN 9 antibody
titer was 1:50 and 1:6,400 in the acute- and convalescent-
phase serum specimens. There was a stable antibody titer to
Hall’s coccus of 1:400 in both. Blood and urine cultures, as
well as other microbiologic tests were negative.
A 68-year-old man was hospitalized on October 15, 1996,
with nausea, vomiting, diarrhea, a nonproductive cough,
shortness of breath, chills, and pleuritic chest pain. The year
before, he had received a cadaveric renal transplant and was
maintained on corticosteroid and cyclosporin therapy. His
oral temperature was 39.2°C, and consolidation was found
on examination of the right lung. A chest radiograph showed
a single lobar opacity on the right. The leukocyte count was
17 x 109/L. S. pneumoniae  was isolated from the sputum.
The patient was treated with cefuroxime intravenously for 4
days and was discharged on oral cefaclor. He made an
uneventful recovery. The acute- and convalescent-phase
titers to BN 9 were stable at 1:400. 
LLAP 4 Infection
Four patients met our definition for infection with LLAP
4 (Table 2). Appearance of pneumonia was similar in all four
chest radiographs. Patient ML 13 had diffuse interstitial
infiltrates, but this patient, who had had a bone marrow
transplant, also had RSV infection. All patients with LLAP 4
recovered from pneumonia. 
Conclusions
In August 1986, Rowbotham (19) isolated LLAP 1 from
the sputum of an 82-year-old woman with persistent
Table1.Percent seropositivity (antibody titer  >1:50) to various
antigens among three study groupsa
Antigen
Healthy 
Nova
Scotians (%)
N = 511 
Ambulatory
pneumonia 
(%)
N = 121
CAP requiring
hospitalization 
(%)
N = 255
LLAP-1 0.19 1.6 0.7
LLAP–2 0 0 0.39
LLAP–3 0.39 1.6 0.7
LLAP-4 0.39 0 4.3
LLAP–6 0.1 0 0.39
LLAP-7 1.36 0 1.56
LLAP–9 0.39 1.6 0.7
LLAP-10 0 0 0.7
LLAP-12 0.97 1.6 0.39
Hall’s coccus 0 1.6 2.35
BN 9 0 0 2.35
Afipia felis 0 0.82 0
aAs defined in paper.
CAP = community-acquired pneumonia.Dispatches
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pneumonia, by cocultivation with A. polyphaga. Seroconver-
sion was demonstrated to LLAP 3. He screened >5,000
serum specimens submitted for Legionella antibody testing
and found that 10 patients met the criteria for infection with
LLAP 3 (19).
The only other study similar to ours is a study by Ben-
son et al. (20), who examined 500 patients with community-
acquired pneumonia and determined antibody titers to
LLAP 1,2,3,4,6,7,9, and Hall’s coccus; 94 (18.9%) had a four-
fold rise in antibody titer of >128 to any LLAP; 36 (7.2%) had
a titer rise to >1,024. In contrast, 1.4% of our 255 hospital-
ized patients with community-acquired pneumonia had evi-
dence of recent infection with a LLAP or Hall’s coccus. As in
our series, LLAP 4 was the most common cause of infection
in the Benson study, which also found that in 10 (10.6%) of
94 patients with LLAP or Hall’s coccus infection a copatho-
gen had been implicated as cause of the pneumonia. Like-
wise, almost all our patients with LLAP infection were
infected with another pathogen.
One of the most interesting findings in our study was a
fourfold rise in antibody titer to BN 19 in a patient with pre-
sumed adult-onset Kawasaki syndrome, an acute vasculitis
of unknown cause found predominantly in infants and young
children. The diagnostic criteria include fever of >5 days plus
four of the following five features: bilateral conjunctivitis
without exudate; polymorphous eruption; cervical lymph
node >1.5 cm in diameter; changes in the extremities, includ-
ing edema of the hands or feet, palm or sole erythema, and
periungual desquamation during convalescence; and
changes in the oropharynx, including fissured red lips,
strawberry tongue, and diffuse erythema of the oropharyn-
geal mucosa (21). Our patient met this definition. An associ-
ation between an antecedent respiratory infection and
Kawasaki syndrome has been described (21,22), as has expo-
sure to freshly cleaned carpets (23,24). It is possible that the
gamma globulin administered to our patient contained anti-
body to BN 19. However, there was no seroconversion or
high titer of antibody to any of the other antigens included in
our test panel. A possible association between infection with
BN 19 and Kawasaki syndrome is easily tested.
Strengths of this study are its size and the comprehen-
siveness of the diagnostic work-up. Its limitations include
the following: the three populations were enrolled in differ-
ent periods; we tested only a subset of the patients hospital-
ized with community-acquired pneumonia and these
patients were from multiple centers across Canada; our com-
parison groups (healthy persons and patients with ambula-
tory pneumonia) were Nova Scotians. However, the
inferences that we are making are limited to the rate of
infection in these three separate groups and are not intended
to indicate differences temporally or geographically.
Our data suggest that LLAPs play a role, albeit an infre-
quent one, in community-acquired pneumonia. Usually they
are a copathogen, but in some cases they are the sole patho-
gen. The possible association between BN 9 and Kawasaki
disease requires further study.  
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